On World Lung Cancer Day, Adalvo highlights its commitment to improving access to high-quality, life-extending treatments for patients affected by lung cancer, the leading cause of cancer-related deaths worldwide.
With millions of patients facing late-stage diagnoses and limited treatment options, the need for accessible, effective therapies has never been greater. Adalvo continues to invest in this area through a growing portfolio that spans both established chemotherapies and next-generation targeted therapies.
Following the launches of Gefitinib and Vinorelbine, and the granting of EU marketing authorisations for Nintedanib, Adalvo has made significant progress in bringing lung cancer treatments to market. Ongoing efforts include regulatory progress for Afatinib, with its DCP having already been submitted and is now pending approval. In parallel, development efforts are ongoing for Osimertinib and Alectinib.
This pipeline reflects Adalvo’s focus on high-barrier oncology assets that combine therapeutic value with strategic execution. Our approach is designed to address unmet clinical needs while enabling our partners to navigate complex markets with confidence.
To explore collaboration opportunities within our oncology portfolio, contact the team today.